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OBJECTIVE — To investigate the association between dietary n-3 long-chain polyunsatu-
rated fatty acids (n-3 LC-PUFAs) and the degree and development of albuminuria in type 1
diabetes.
RESEARCH DESIGN AND METHODS — We analyzed longitudinal data from 1,436
participants in the Diabetes Control and Complications Trial. We deﬁned the average intake of
eicosapentaenoic and docosahexaenoic acid from diet histories. Urinary albumin excretion rates
(UAERs) were measured over 24 h; incident albuminuria was considered the ﬁrst occurrence of
an UAER 40 mg/24 h sustained for 1 year in normoalbuminuric individuals.
RESULTS — In a mean follow-up of 6.5 years, we observed a lower mean UAER (difference
22.7 mg/24 h [95% CI 1.6–43.8)]) in the top versus the bottom third of dietary n-3 LC-PUFAs,
but we found no association with incident albuminuria.
CONCLUSIONS — Dietary n-3 LC-PUFAs appear inversely associated with the degree but
not with the incidence of albuminuria in type 1 diabetes. These ﬁndings require further inves-
tigation in prospective studies.
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ish provides the main dietary source
of n-3 long-chain polyunsaturated
fatty acids (n-3 LC-PUFAs) includ-
ing eicosapentaenoic acid (EPA) and do-
cosahexaenoicacid(DHA)(1).Unlikefor
macrovascular complications, con-
sumption of ﬁsh or ﬁsh oils and their
associations to diabetic microvascular
complicationsislesswellstudied.Trials
of supplementation with n-3 LC-PUFAs
on urinary albumin excretion rate
(UAER) in diabetes exist but taken to-
gether did not show a signiﬁcant effect
(2). In cross-sectional analyses, ﬁsh con-
sumptionwasassociatedwithalowerrisk
of macroalbuminuria in type 2 diabetes
(3). Whether n-3 LC-PUFAs accounted
for these beneﬁcial effects is not clear. No
observational study has investigated the
association between n-3 LC-PUFAs ex-
clusively from dietary intake and diabetic
nephropathy. In this study, we examined
the association between dietary n-3 LC-
PUFAs and incident albuminuria and
changes in UAER over time in type 1
diabetes.
RESEARCH DESIGN AND
METHODS— The study population
included 1,436 individuals aged 13 to 39
with type 1 diabetes who participated in
the Diabetes Control and Complications
Trial (DCCT) between 1983 and 1993
with baseline information on dietary n-3
LC-PUFAs (4). We deﬁned dietary n-3
LC-PUFAs as the sum of the average in-
take of EPA and DHA in g/day obtained
fromamodiﬁedBurke-typediethistoryat
baseline (5), which provided data on the
nutrient composition of a diet instead of
food quantities. UAER was measured an-
nuallyasalbuminexcretionina4-htimed
urine specimen. Incident albuminuria
was deﬁned as the ﬁrst occurrence of
UAER of 40 mg/24 h sustained for 1
year in normoalbuminuric individuals at
baseline (6).
We used mixed-effects regression
models with random intercepts to esti-
mate the association between thirds of
dietary n-3 LC-PUFAs and repeated mea-
surements of UAER (7). We tested for
interaction to assess whether this associa-
tiondifferedbetweentheprimarypreven-
tion and the secondary intervention
cohorts or between treatment groups. We
used proportional hazards regression
models to estimate the association be-
tweendietaryn-3LC-PUFAsandincident
albuminuria. The data for this analysis
came from a public domain (8).
RESULTS— Among the 1,362 nor-
moalbuminuric participants at baseline,
95 people developed albuminuria in a
mean follow-up of 6.5 years. Participants
with dietary n-3 LC-PUFAs in the upper
third were more likely to be male, older,
consume alcohol, use dietary supple-
ments,plushavehigherBMIandintakeof
energy and protein but lower UAER, ver-
sus participants in the lowest third of
intake.
In unadjusted mixed-effects regres-
sion analyses, the mean UAER was 28.1
mg/24 h (95% CI 6.1–50.0, P  0.01)
lower in participants, comparing the top
with the bottom third of dietary n-3 LC-
PUFAs. In adjusted analyses, the differ-
ence in mean UAER narrowed to 22.7
mg/24 h (1.6–43.8, P  0.04).
We observed a signiﬁcant interaction
between dietary n-3 LC-PUFAs and treat-
mentgroups(P0.005)andaborderline
signiﬁcant interaction by cohort (P 
0.06) for the difference in mean UAER. In
adjusted stratiﬁed analyses, the mean
UAER was 40.2 mg/24 h (95% CI 1.3–
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sive) treatment group and was 45.5
mg/24 h (4.8–86.2) lower in the second-
ary intervention (vs. primary prevention)
cohort, comparing extreme thirds of di-
etary n-3 LC-PUFAs (Table 1). We found
no signiﬁcant associations between di-
etary n-3 LC-PUFAs and incident albu-
minuria in unadjusted (hazard ratio [HR]
0.76 [95% CI 0.47–1.23]) or adjusted
proportional hazard regression analyses
(1.19 [0.72–2.00]).
CONCLUSIONS — In this cohort,
consumption of dietary n-3 LC-PUFAs
wasassociatedwithaslowerdeterioration
of albumin excretion, but not with inci-
dent albuminuria in type 1 diabetes. We
observed an association only in the con-
ventionaltreatmentgroup,whichmayre-
ﬂect a chance ﬁnding or intensive
glycemic control may obscure an effect of
n-3 LC-PUFAs on albuminuria (6). Di-
etary counseling is unlikely to have ac-
counted for this, since it was not focused
on speciﬁc food choices (4). In further
support, we observed no difference be-
tweentreatmentgroupsinn-3LC-PUFAs
consumed per kcal at baseline and at year
2 of follow-up. If dietary n-3 LC-PUFAs
improves albuminuria, the effect may dif-
fer by level of glycemia. We observed that
a higher intake of n-3 LC-PUFAs was as-
sociatedwithlowerlevelsofUAERonlyin
participants with values of A1C above the
median (7.7%) (data not shown). Inﬂam-
mation perhaps accounts for this, since
advanced glycated end products activate
nuclear factor-B (NF-B), which stimu-
lates production of chemokine monocyte
chemoattractant protein (MCP)-1 (9). As




We show that dietary n-3 LC-PUFAs
are associated with a slower deterioration
of UAER only in the secondary interven-
tion cohort. We have previously re-
ported an inverse association between
ﬁsh consumption and macroalbumin-
uria—but not microalbuminuria—in
type 2 diabetes (3). Urinary MCP-1 is
higher in macroalbuminuric diabetic
patients than in those with normoalbu-
minuria or microalbuminuria (11). If
dietary n-3 LC-PUFAs decrease UAER
via anti-inﬂammatory mechanisms, one
might expect the association to be greater
in more advanced stages of nephropathy.
This may also explain, in part, why di-
etary n-3 LC-PUFAs are not associated
with incident albuminuria.
ThestrengthsoftheDCCTincludeits
design and repeated measurements of
UAER. Because of missing values during
follow-up, we conﬁned our analyses to
dietary data at baseline, a decision un-
likelytohavebiasedourresultsgiventhat
the Burke-type diet history is highly re-
producible (12). We did not have infor-
mation on plasma n-3 LC-PUFAs, an
objective biomarker of ﬁsh consumption
(13). However, the use of the Burke-type
diet history increases the validity of our
measurement of exposure. We observed
no change in the results when restricting
data to the ﬁrst 4 years of follow-up with
few missing values of UAER. We had no
information on the use of ACE inhibitors,
which we assume few participants took
before 1993.
Thecurrentstudyprovidesabasisfor
further prospective studies that examine
the effects of dietary n-3 LC-PUFAs on
albuminuria, measuring biomarkers in-
cluding plasma n-3 LC-PUFAs, and
exploring potential mechanisms of in-
ﬂammation. At present, we recommend
that clinicians promote current guidance
on ﬁsh consumption of two portions per
week (14).
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